NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

**NICE INDICATOR GUIDANCE**

**Resource impact statement: NM209**

**Date first published on NICE menu:** August 2022

# Indicator

**NM209.** The percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months.

# Resource impact

The prevalence of adults receiving drug treatment for epilepsy is around 0.8% ([Quality and Outcomes Framework, 2020-21](https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/2020-21)). This is equivalent to around 63 adults per 10,000 population ([Office for National Statistics, 2020](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/datasets/birthsummarytables)).

Robust data for the number of these people who had a structured review in the preceding 12 months are not available. It is estimated that for every 10% increase in the number of people in this population who have a structured review, an additional 6 people per GP practice will have a structured review (see table 1).

**Table 1 Estimated impact on activity for a theoretical 1%, 5% and 10% increase in the proportion of adults having a structured review.**

Estimated impact on activity for a theoretical 1%, 5% and 10% increase in the proportion of adults having a structured review. This is based on 10,000 registered patients in a GP practice. 

This is based on 10,000 registered patients in a GP practice.

Due to the small numbers involved, the impact on general practice is anticipated to be minimal and the resource impact associated with any increase will not be significant.